Announcement on Earnings Preannouncement for 2025
Filed with SSE · · 2 pages · Chinese
CanSino Biologics, Inc. on 6ix
Earlier from CanSino Biologics
- Announcement on Obtaining Notice of Approval for Drug Clinical Trial for 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197, TT)
- Announcement on Voluntary Disclosure of the Initiation of Phase I Clinical Trial of the Adsorbed Acellular Pertussis (Component), Diphtheria and Tetanus, Haemophilus influenzae Type b (Conjugate) – Meningococcal ACYW-135 (Conjugate) Combination Vaccine and the Completion of Enrollment of the First Subject
- Announcement on Notifying the Creditors of Offsetting Losses with Capital Reserve
- Announcement on Implementation of Cancellation of Repurchased A-shares
- Announcement on Voluntary Disclosure of the Initiation of Phase 1 Clinical Trial and Completion of 1st Subject Enrollment for Inhalable Tuberculosis Vaccine (Type 5 Adenovirus Vector) in Indonesia
Later from CanSino Biologics
- CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines
- Announcement on Obtaining the Supplementary Application Approval Notice for the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Carrier)
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Voluntary Disclosure of Obtaining PIC/S GMP Certification
- Announcement on Requesting the General Meeting to Authorize the Board of Directors to Issue Shares to Specific Objects by Summary Procedure
Follow CanSino Biologics into a list and get an email when it puts out news.
Follow CanSino Biologics